» Articles » PMID: 22259602

Culprit-Lesion-Only Versus Multivessel Revascularization Using Drug-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: A Korean Acute Myocardial Infarction Registry-Based Analysis

Abstract

Background And Objectives: In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease, complete revascularization (CR) for non-culprit lesions is not routinely recommended. The aim of this study was to compare the clinical outcomes of multivessel compared with infarct-related artery (IRA)-only revascularization in patients undergoing primary percutaneous coronary intervention (PCI) for STEMI.

Subjects And Methods: From the Korean Acute Myocardial Infarction Registry (KAMIR) database, 1,094 STEMI patients with multivessel disease who underwent primary PCI with drug-eluting stents were enrolled in this study. The patients were divided into two groups: culprit-vessel-only revascularization (COR, n=827) group; multivessel revascularization, including non-IRA (MVR, n=267) group. The primary endpoint of this study included major adverse cardiac events (MACEs), such as death, myocardial infarction, or target or nontarget lesion revascularization at one year.

Results: There was no difference in clinical characteristics between the two groups. During the one-year follow-up, 102 (15.2%) patients in the COR group and 32 (14.2%) in the MVR group experienced at least one MACE (p=0.330). There were no differences between the two groups in terms of rates of death, myocardial infarction, or revascularization (2.1% vs. 2.0%, 0.7% vs. 0.8%, and 11.7% vs. 10.1%, respectively; p=0.822, 0.910, and 0.301, respectively). The MACE rate was higher in the incompletely revascularized patients than in the completely revascularized patients (15% vs. 9.5%, p=0.039), and the difference was attributable to a higher rate of nontarget vessel revascularization (8.6% vs. 1.8%, p=0.002).

Conclusion: Although multivessel angioplasty during primary PCI for STEMI did not reduce the MACE rate compared with culprit-vessel-only PCI, CR was associated with a lower rate of repeat revascularization after multivessel PCI.

Citing Articles

Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD): A Multicenter, Randomized, Controlled Trial.

Tian J, Wang Z, Wang Y, Wang F, Wang Y, Zhao P Clin Cardiol. 2024; 47(12):e70049.

PMID: 39587825 PMC: 11589165. DOI: 10.1002/clc.70049.


Complete Versus Culprit-Only Revascularization in STEMI: a Contemporary Review.

Lu D, Zhong M, Feldman D Curr Treat Options Cardiovasc Med. 2018; 20(5):41.

PMID: 29627944 DOI: 10.1007/s11936-018-0636-9.


Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease.

Bravo C, Hirji S, Bhatt D, Kataria R, Faxon D, Ohman E Cochrane Database Syst Rev. 2017; 5:CD011986.

PMID: 28470696 PMC: 6481381. DOI: 10.1002/14651858.CD011986.pub2.


Immediate multivessel revascularization may increase cardiac death and myocardial infarction in patients with ST-elevation myocardial infarction and multivessel coronary artery disease: data analysis from real world practice.

Chung W, Seo J, Choi D, Cho Y, Lee J, Suh J Korean J Intern Med. 2016; 31(3):488-500.

PMID: 27048252 PMC: 4855085. DOI: 10.3904/kjim.2014.119.


Complete infarct-related artery revascularization in acute myocardial infarction patients. CORAMI Registry.

Siudak Z, Mrevlje B, Janus B, Dziewierz A, Rakowski T, Legutko J Postepy Kardiol Interwencyjnej. 2015; 11(2):84-8.

PMID: 26161098 PMC: 4495122. DOI: 10.5114/pwki.2015.52279.


References
1.
Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M . Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009; 150(3):170-7. DOI: 10.7326/0003-4819-150-3-200902030-00006. View

2.
Kim M, Jeong M, Ahn Y, Kim J, Chae S, Kim Y . What is optimal revascularization strategy in patients with multivessel coronary artery disease in non-ST-elevation myocardial infarction? Multivessel or culprit-only revascularization. Int J Cardiol. 2010; 153(2):148-53. DOI: 10.1016/j.ijcard.2010.08.044. View

3.
Lee M, Jeong M, Ahn Y, Chae S, Hur S, Hong T . Impact of the metabolic syndrome on the clinical outcome of patients with acute ST-elevation myocardial infarction. J Korean Med Sci. 2010; 25(10):1456-61. PMC: 2946655. DOI: 10.3346/jkms.2010.25.10.1456. View

4.
Brener S, Milford-Beland S, Roe M, Bhatt D, Weintraub W, Brindis R . Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. Am Heart J. 2007; 155(1):140-6. DOI: 10.1016/j.ahj.2007.09.007. View

5.
Lee S, Jeong M, Ahn Y, Chae S, Hur S, Kim Y . Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry. Circ J. 2008; 72(3):392-8. DOI: 10.1253/circj.72.392. View